EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial
Identifieur interne : 000335 ( France/Analysis ); précédent : 000334; suivant : 000336EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial
Auteurs : H. Cheng [États-Unis] ; K. Ballman [États-Unis] ; M. Vassilakopoulou [France] ; A. C. Dueck [États-Unis] ; M. M. Reinholz [États-Unis] ; K. Tenner [États-Unis] ; J. Gralow [États-Unis] ; C. Hudis [États-Unis] ; N. E. Davidson [États-Unis] ; G. Fountzilas [Grèce] ; A. E. Mccullough [États-Unis] ; B. Chen [États-Unis] ; A. Psyrri [Grèce] ; D. L. Rimm [États-Unis] ; E. A. Perez [États-Unis]Source :
- British journal of cancer [ 0007-0920 ] ; 2014.
Descripteurs français
- KwdFr :
- Adulte d'âge moyen, Analyse sur puce à tissus, Anticorps monoclonaux humanisés (administration et posologie), Femelle, Humains, Marqueurs biologiques tumoraux (analyse), Protocoles de polychimiothérapie antinéoplasique (administration et posologie), Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique), Récepteur ErbB-2 (analyse), Récepteur du facteur de croissance épidermique (analyse), Survie sans rechute, Taux de survie, Trastuzumab, Tumeurs du sein (), Tumeurs du sein (traitement médicamenteux), Études de suivi.
- MESH :
- administration et posologie : Anticorps monoclonaux humanisés, Protocoles de polychimiothérapie antinéoplasique.
- analyse : Marqueurs biologiques tumoraux, Récepteur ErbB-2, Récepteur du facteur de croissance épidermique.
- traitement médicamenteux : Tumeurs du sein.
- usage thérapeutique : Protocoles de polychimiothérapie antinéoplasique.
- Pascal (Inist)
- Adulte d'âge moyen, Analyse sur puce à tissus, Femelle, Humains, Immunofluorescence, Récepteur facteur croissance épiderme, Association, Cancer du sein, Survie sans rechute, Taux de survie, Trastuzumab, Essai clinique, Récepteur facteur croissance, Marqueur biologique, Dosage, Cancérologie, Anticancéreux, Immunomodulateur, Tumeurs du sein, Études de suivi.
- Wicri :
- topic : Association.
English descriptors
- KwdEn :
- Antibodies, Monoclonal, Humanized (administration & dosage), Antineoplastic Combined Chemotherapy Protocols (administration & dosage), Antineoplastic Combined Chemotherapy Protocols (therapeutic use), Antineoplastic agent, Assay, Association, Biological marker, Biomarkers, Tumor (analysis), Breast Neoplasms (chemistry), Breast Neoplasms (drug therapy), Breast cancer, Cancerology, Clinical trial, Disease-Free Survival, Epidermal growth factor receptor, Female, Follow-Up Studies, Growth factor receptor, Humans, Immunofluorescence, Immunomodulator, Middle Aged, Receptor, Epidermal Growth Factor (analysis), Receptor, ErbB-2 (analysis), Survival Rate, Tissue Array Analysis, Trastuzumab.
- MESH :
- chemical , administration & dosage : Antibodies, Monoclonal, Humanized.
- administration & dosage : Antineoplastic Combined Chemotherapy Protocols.
- chemical , analysis : Biomarkers, Tumor, Receptor, Epidermal Growth Factor, Receptor, ErbB-2.
- chemistry : Breast Neoplasms.
- drug therapy : Breast Neoplasms.
- therapeutic use : Antineoplastic Combined Chemotherapy Protocols.
- Disease-Free Survival, Female, Follow-Up Studies, Humans, Middle Aged, Survival Rate, Tissue Array Analysis, Trastuzumab.
Abstract
Background: Epidermal growth factor receptor (EGFR) has been hypothesised to modulate the effectiveness of anti-HER2 therapy. We used a standardised, quantitative immunofluorescence assay and a novel EGFR antibody to evaluate the correlation between EGFR expression and clinical outcome in the North Central Cancer Treatment Group (NCCTG) N9831 trial. Methods: Tissue microarrays were constructed that allowed analysis of 1365 patients randomly assigned to receive chemotherapy alone (Arm A), sequential trastuzumab after chemotherapy (Arm B) and chemotherapy with concurrent trastuzumab (Arm C). Measurement of EGFR was performed using the EGFR antibody, D38B1, on the fluorescence-based AQUA platform. The result was validated using an independent retrospective metastatic breast cancer cohort (n=130). Results: Epidermal growth factor receptor assessed as a continuous (logarithmic transformed) variable shows an association with disease-free survival in Arm C (P= 0.009) but not in Arm A or B. High EGFR expression was associated with worse outcome (Hazard ratio (HR) = 2.15; 95% CI 1.28-3.60, P= 0.004). Validation in a Greek metastatic breast cancer cohort showed an HR associated with high EGFR expression of 1.92 (P=0.0073). Conclusions: High expression of EGFR appears to be associated with decreased benefit from adjuvant concurrent trastuzumab. Since other treatment options exist for HER2-driven tumours, further validation of these data may select patients for alternative or additive therapy.
Url:
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 000507
- to stream PascalFrancis, to step Curation: 004130
- to stream PascalFrancis, to step Checkpoint: 000996
- to stream Main, to step Merge: 005919
- to stream Pmc, to step Corpus: 000366
- to stream Pmc, to step Curation: 000366
- to stream Pmc, to step Checkpoint: 001535
- to stream PubMed, to step Corpus: 001D63
- to stream PubMed, to step Curation: 001D54
- to stream PubMed, to step Checkpoint: 001D54
- to stream Ncbi, to step Merge: 002F02
- to stream Ncbi, to step Curation: 002F02
- to stream Ncbi, to step Checkpoint: 002F02
- to stream Main, to step Merge: 003385
- to stream Main, to step Curation: 005609
- to stream Main, to step Exploration: 005609
- to stream France, to step Extraction: 000335
Links to Exploration step
Pascal:14-0250912Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial</title><author><name sortKey="Cheng, H" sort="Cheng, H" uniqKey="Cheng H" first="H." last="Cheng">H. Cheng</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Pathology, Yale University School of Medicine, 310 Cedar Street BML116</s1><s2>New Haven, CT 06520</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>14 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>New Haven, CT 06520</wicri:noRegion></affiliation></author><author><name sortKey="Ballman, K" sort="Ballman, K" uniqKey="Ballman K" first="K." last="Ballman">K. Ballman</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Division of Biomedical Statistics and Informatics, Mayo Clinic, 200 First Street Southwest</s1><s2>Rochester, MN 55905</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Rochester, MN 55905</wicri:noRegion></affiliation></author><author><name sortKey="Vassilakopoulou, M" sort="Vassilakopoulou, M" uniqKey="Vassilakopoulou M" first="M." last="Vassilakopoulou">M. Vassilakopoulou</name><affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Department of Medical Oncology, Pitie-Salpetriere Hospital, 83 Boulevard de l'Hopital</s1><s2>75013 Paris</s2><s3>FRA</s3><sZ>3 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Dueck, A C" sort="Dueck, A C" uniqKey="Dueck A" first="A. C." last="Dueck">A. C. Dueck</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Section of Biostatistics, Mayo Clinic, 13400 East Shea Boulevard</s1><s2>Scottsdale, AZ 85259</s2><s3>USA</s3><sZ>4 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Scottsdale, AZ 85259</wicri:noRegion></affiliation></author><author><name sortKey="Reinholz, M M" sort="Reinholz, M M" uniqKey="Reinholz M" first="M. M." last="Reinholz">M. M. Reinholz</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Laboratory Medicine and Pathology, Mayo Clinic, 200 First Street Southwest</s1><s2>Rochester, MN 55905</s2><s3>USA</s3><sZ>5 aut.</sZ><sZ>12 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Rochester, MN 55905</wicri:noRegion></affiliation></author><author><name sortKey="Tenner, K" sort="Tenner, K" uniqKey="Tenner K" first="K." last="Tenner">K. Tenner</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Division of Biomedical Statistics and Informatics, Mayo Clinic, 200 First Street Southwest</s1><s2>Rochester, MN 55905</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Rochester, MN 55905</wicri:noRegion></affiliation></author><author><name sortKey="Gralow, J" sort="Gralow, J" uniqKey="Gralow J" first="J." last="Gralow">J. Gralow</name><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Department of Medical Oncology, University of Washington/ Seattle Cancer Care Alliance, 825 Eastlake Avenue East</s1><s2>Seattle, WA 98109</s2><s3>USA</s3><sZ>7 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Seattle, WA 98109</wicri:noRegion></affiliation></author><author><name sortKey="Hudis, C" sort="Hudis, C" uniqKey="Hudis C" first="C." last="Hudis">C. Hudis</name><affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Department of Medical Oncology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, Box 8</s1><s2>New York, NY 10065</s2><s3>USA</s3><sZ>8 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>New York, NY 10065</wicri:noRegion></affiliation></author><author><name sortKey="Davidson, N E" sort="Davidson, N E" uniqKey="Davidson N" first="N. E." last="Davidson">N. E. Davidson</name><affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Division of Hematology/Oncology, University of Pittsburgh Cancer Institute and UPMC Cancer Center, 5150 Centre Avenue</s1><s2>Pittsburgh, PA 15232</s2><s3>USA</s3><sZ>9 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Pittsburgh, PA 15232</wicri:noRegion></affiliation></author><author><name sortKey="Fountzilas, G" sort="Fountzilas, G" uniqKey="Fountzilas G" first="G." last="Fountzilas">G. Fountzilas</name><affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Department of Medical Oncology, Papageorgiou General Hospital, Aristotle University of Thessaloniki School of Medicine, Efkarpia Peripheral Road Stavroupoli</s1><s2>56429 Thessaloniki</s2><s3>GRC</s3><sZ>10 aut.</sZ></inist:fA14><country>Grèce</country><wicri:noRegion>56429 Thessaloniki</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Hellenic Cooperative Oncology Group (HeCOG), Laskaridou 1</s1><s2>11524 Athens</s2><s3>GRC</s3><sZ>10 aut.</sZ><sZ>13 aut.</sZ></inist:fA14><country>Grèce</country><placeName><settlement type="city">Athènes</settlement><region nuts="2" type="region">Attique (région)</region></placeName></affiliation></author><author><name sortKey="Mccullough, A E" sort="Mccullough, A E" uniqKey="Mccullough A" first="A. E." last="Mccullough">A. E. Mccullough</name><affiliation wicri:level="1"><inist:fA14 i1="11"><s1>Anatomic Pathology, Mayo Clinic, 13400 E Shea Blvd</s1><s2>Scottsdale, AZ 85259</s2><s3>USA</s3><sZ>11 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Scottsdale, AZ 85259</wicri:noRegion></affiliation></author><author><name sortKey="Chen, B" sort="Chen, B" uniqKey="Chen B" first="B." last="Chen">B. Chen</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Laboratory Medicine and Pathology, Mayo Clinic, 200 First Street Southwest</s1><s2>Rochester, MN 55905</s2><s3>USA</s3><sZ>5 aut.</sZ><sZ>12 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Rochester, MN 55905</wicri:noRegion></affiliation></author><author><name sortKey="Psyrri, A" sort="Psyrri, A" uniqKey="Psyrri A" first="A." last="Psyrri">A. Psyrri</name><affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Hellenic Cooperative Oncology Group (HeCOG), Laskaridou 1</s1><s2>11524 Athens</s2><s3>GRC</s3><sZ>10 aut.</sZ><sZ>13 aut.</sZ></inist:fA14><country>Grèce</country><placeName><settlement type="city">Athènes</settlement><region nuts="2" type="region">Attique (région)</region></placeName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="12"><s1>Second Department of Internal Medicine Propaedeutic, Oncology Section, Attikon University Hospital, University of Athens Medical School, 1 Rimini Street</s1><s2>Haidari, 12462 Athens</s2><s3>GRC</s3><sZ>13 aut.</sZ></inist:fA14><country>Grèce</country><placeName><settlement type="city">Athènes</settlement><region nuts="2" type="region">Attique (région)</region></placeName></affiliation></author><author><name sortKey="Rimm, D L" sort="Rimm, D L" uniqKey="Rimm D" first="D. L." last="Rimm">D. L. Rimm</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Pathology, Yale University School of Medicine, 310 Cedar Street BML116</s1><s2>New Haven, CT 06520</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>14 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>New Haven, CT 06520</wicri:noRegion></affiliation></author><author><name sortKey="Perez, E A" sort="Perez, E A" uniqKey="Perez E" first="E. A." last="Perez">E. A. Perez</name><affiliation wicri:level="1"><inist:fA14 i1="13"><s1>Department of Hematology/Oncology, Mayo Clinic, 4500 San Pablo Road</s1><s2>Jacksonville, FL 32224</s2><s3>USA</s3><sZ>15 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Jacksonville, FL 32224</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">14-0250912</idno><date when="2014">2014</date><idno type="stanalyst">PASCAL 14-0250912 INIST</idno><idno type="RBID">Pascal:14-0250912</idno><idno type="wicri:Area/PascalFrancis/Corpus">000507</idno><idno type="wicri:Area/PascalFrancis/Curation">004130</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000996</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000996</idno><idno type="wicri:doubleKey">0007-0920:2014:Cheng H:egfr:expression:is</idno><idno type="wicri:Area/Main/Merge">005919</idno><idno type="wicri:source">PMC</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4453859</idno><idno type="RBID">PMC:4453859</idno><idno type="wicri:Area/Pmc/Corpus">000366</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000366</idno><idno type="wicri:Area/Pmc/Curation">000366</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000366</idno><idno type="wicri:Area/Pmc/Checkpoint">001535</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">001535</idno><idno type="wicri:source">PubMed</idno><idno type="wicri:Area/PubMed/Corpus">001D63</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001D63</idno><idno type="wicri:Area/PubMed/Curation">001D54</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001D54</idno><idno type="wicri:Area/PubMed/Checkpoint">001D54</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001D54</idno><idno type="wicri:Area/Ncbi/Merge">002F02</idno><idno type="wicri:Area/Ncbi/Curation">002F02</idno><idno type="wicri:Area/Ncbi/Checkpoint">002F02</idno><idno type="wicri:doubleKey">0007-0920:2014:Cheng H:egfr:expression:is</idno><idno type="wicri:Area/Main/Merge">003385</idno><idno type="wicri:Area/Main/Curation">005609</idno><idno type="wicri:Area/Main/Exploration">005609</idno><idno type="wicri:Area/France/Extraction">000335</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial</title><author><name sortKey="Cheng, H" sort="Cheng, H" uniqKey="Cheng H" first="H." last="Cheng">H. Cheng</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Pathology, Yale University School of Medicine, 310 Cedar Street BML116</s1><s2>New Haven, CT 06520</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>14 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>New Haven, CT 06520</wicri:noRegion></affiliation></author><author><name sortKey="Ballman, K" sort="Ballman, K" uniqKey="Ballman K" first="K." last="Ballman">K. Ballman</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Division of Biomedical Statistics and Informatics, Mayo Clinic, 200 First Street Southwest</s1><s2>Rochester, MN 55905</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Rochester, MN 55905</wicri:noRegion></affiliation></author><author><name sortKey="Vassilakopoulou, M" sort="Vassilakopoulou, M" uniqKey="Vassilakopoulou M" first="M." last="Vassilakopoulou">M. Vassilakopoulou</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Medical Oncology, Pitie-Salpetriere Hospital, 83 Boulevard de l'Hopital</s1><s2>75013 Paris</s2><s3>FRA</s3><sZ>3 aut.</sZ></inist:fA14><country>France</country><wicri:noRegion>75013 Paris</wicri:noRegion><placeName><settlement type="city">Paris</settlement><region type="région" nuts="2">Île-de-France</region></placeName></affiliation></author><author><name sortKey="Dueck, A C" sort="Dueck, A C" uniqKey="Dueck A" first="A. C." last="Dueck">A. C. Dueck</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Section of Biostatistics, Mayo Clinic, 13400 East Shea Boulevard</s1><s2>Scottsdale, AZ 85259</s2><s3>USA</s3><sZ>4 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Scottsdale, AZ 85259</wicri:noRegion></affiliation></author><author><name sortKey="Reinholz, M M" sort="Reinholz, M M" uniqKey="Reinholz M" first="M. M." last="Reinholz">M. M. Reinholz</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Laboratory Medicine and Pathology, Mayo Clinic, 200 First Street Southwest</s1><s2>Rochester, MN 55905</s2><s3>USA</s3><sZ>5 aut.</sZ><sZ>12 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Rochester, MN 55905</wicri:noRegion></affiliation></author><author><name sortKey="Tenner, K" sort="Tenner, K" uniqKey="Tenner K" first="K." last="Tenner">K. Tenner</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Division of Biomedical Statistics and Informatics, Mayo Clinic, 200 First Street Southwest</s1><s2>Rochester, MN 55905</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Rochester, MN 55905</wicri:noRegion></affiliation></author><author><name sortKey="Gralow, J" sort="Gralow, J" uniqKey="Gralow J" first="J." last="Gralow">J. Gralow</name><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Department of Medical Oncology, University of Washington/ Seattle Cancer Care Alliance, 825 Eastlake Avenue East</s1><s2>Seattle, WA 98109</s2><s3>USA</s3><sZ>7 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Seattle, WA 98109</wicri:noRegion></affiliation></author><author><name sortKey="Hudis, C" sort="Hudis, C" uniqKey="Hudis C" first="C." last="Hudis">C. Hudis</name><affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Department of Medical Oncology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, Box 8</s1><s2>New York, NY 10065</s2><s3>USA</s3><sZ>8 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>New York, NY 10065</wicri:noRegion></affiliation></author><author><name sortKey="Davidson, N E" sort="Davidson, N E" uniqKey="Davidson N" first="N. E." last="Davidson">N. E. Davidson</name><affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Division of Hematology/Oncology, University of Pittsburgh Cancer Institute and UPMC Cancer Center, 5150 Centre Avenue</s1><s2>Pittsburgh, PA 15232</s2><s3>USA</s3><sZ>9 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Pittsburgh, PA 15232</wicri:noRegion></affiliation></author><author><name sortKey="Fountzilas, G" sort="Fountzilas, G" uniqKey="Fountzilas G" first="G." last="Fountzilas">G. Fountzilas</name><affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Department of Medical Oncology, Papageorgiou General Hospital, Aristotle University of Thessaloniki School of Medicine, Efkarpia Peripheral Road Stavroupoli</s1><s2>56429 Thessaloniki</s2><s3>GRC</s3><sZ>10 aut.</sZ></inist:fA14><country>Grèce</country><wicri:noRegion>56429 Thessaloniki</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Hellenic Cooperative Oncology Group (HeCOG), Laskaridou 1</s1><s2>11524 Athens</s2><s3>GRC</s3><sZ>10 aut.</sZ><sZ>13 aut.</sZ></inist:fA14><country>Grèce</country><placeName><settlement type="city">Athènes</settlement><region nuts="2" type="region">Attique (région)</region></placeName></affiliation></author><author><name sortKey="Mccullough, A E" sort="Mccullough, A E" uniqKey="Mccullough A" first="A. E." last="Mccullough">A. E. Mccullough</name><affiliation wicri:level="1"><inist:fA14 i1="11"><s1>Anatomic Pathology, Mayo Clinic, 13400 E Shea Blvd</s1><s2>Scottsdale, AZ 85259</s2><s3>USA</s3><sZ>11 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Scottsdale, AZ 85259</wicri:noRegion></affiliation></author><author><name sortKey="Chen, B" sort="Chen, B" uniqKey="Chen B" first="B." last="Chen">B. Chen</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Laboratory Medicine and Pathology, Mayo Clinic, 200 First Street Southwest</s1><s2>Rochester, MN 55905</s2><s3>USA</s3><sZ>5 aut.</sZ><sZ>12 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Rochester, MN 55905</wicri:noRegion></affiliation></author><author><name sortKey="Psyrri, A" sort="Psyrri, A" uniqKey="Psyrri A" first="A." last="Psyrri">A. Psyrri</name><affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Hellenic Cooperative Oncology Group (HeCOG), Laskaridou 1</s1><s2>11524 Athens</s2><s3>GRC</s3><sZ>10 aut.</sZ><sZ>13 aut.</sZ></inist:fA14><country>Grèce</country><placeName><settlement type="city">Athènes</settlement><region nuts="2" type="region">Attique (région)</region></placeName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="12"><s1>Second Department of Internal Medicine Propaedeutic, Oncology Section, Attikon University Hospital, University of Athens Medical School, 1 Rimini Street</s1><s2>Haidari, 12462 Athens</s2><s3>GRC</s3><sZ>13 aut.</sZ></inist:fA14><country>Grèce</country><placeName><settlement type="city">Athènes</settlement><region nuts="2" type="region">Attique (région)</region></placeName></affiliation></author><author><name sortKey="Rimm, D L" sort="Rimm, D L" uniqKey="Rimm D" first="D. L." last="Rimm">D. L. Rimm</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Pathology, Yale University School of Medicine, 310 Cedar Street BML116</s1><s2>New Haven, CT 06520</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>14 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>New Haven, CT 06520</wicri:noRegion></affiliation></author><author><name sortKey="Perez, E A" sort="Perez, E A" uniqKey="Perez E" first="E. A." last="Perez">E. A. Perez</name><affiliation wicri:level="1"><inist:fA14 i1="13"><s1>Department of Hematology/Oncology, Mayo Clinic, 4500 San Pablo Road</s1><s2>Jacksonville, FL 32224</s2><s3>USA</s3><sZ>15 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Jacksonville, FL 32224</wicri:noRegion></affiliation></author></analytic><series><title level="j" type="main">British journal of cancer</title><title level="j" type="abbreviated">Br. j. cancer</title><idno type="ISSN">0007-0920</idno><imprint><date when="2014">2014</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">British journal of cancer</title><title level="j" type="abbreviated">Br. j. cancer</title><idno type="ISSN">0007-0920</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antibodies, Monoclonal, Humanized (administration & dosage)</term><term>Antineoplastic Combined Chemotherapy Protocols (administration & dosage)</term><term>Antineoplastic Combined Chemotherapy Protocols (therapeutic use)</term><term>Antineoplastic agent</term><term>Assay</term><term>Association</term><term>Biological marker</term><term>Biomarkers, Tumor (analysis)</term><term>Breast Neoplasms (chemistry)</term><term>Breast Neoplasms (drug therapy)</term><term>Breast cancer</term><term>Cancerology</term><term>Clinical trial</term><term>Disease-Free Survival</term><term>Epidermal growth factor receptor</term><term>Female</term><term>Follow-Up Studies</term><term>Growth factor receptor</term><term>Humans</term><term>Immunofluorescence</term><term>Immunomodulator</term><term>Middle Aged</term><term>Receptor, Epidermal Growth Factor (analysis)</term><term>Receptor, ErbB-2 (analysis)</term><term>Survival Rate</term><term>Tissue Array Analysis</term><term>Trastuzumab</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Analyse sur puce à tissus</term><term>Anticorps monoclonaux humanisés (administration et posologie)</term><term>Femelle</term><term>Humains</term><term>Marqueurs biologiques tumoraux (analyse)</term><term>Protocoles de polychimiothérapie antinéoplasique (administration et posologie)</term><term>Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique)</term><term>Récepteur ErbB-2 (analyse)</term><term>Récepteur du facteur de croissance épidermique (analyse)</term><term>Survie sans rechute</term><term>Taux de survie</term><term>Trastuzumab</term><term>Tumeurs du sein ()</term><term>Tumeurs du sein (traitement médicamenteux)</term><term>Études de suivi</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antibodies, Monoclonal, Humanized</term></keywords><keywords scheme="MESH" qualifier="administration & dosage" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Anticorps monoclonaux humanisés</term><term>Protocoles de polychimiothérapie antinéoplasique</term></keywords><keywords scheme="MESH" qualifier="analyse" xml:lang="fr"><term>Marqueurs biologiques tumoraux</term><term>Récepteur ErbB-2</term><term>Récepteur du facteur de croissance épidermique</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Biomarkers, Tumor</term><term>Receptor, Epidermal Growth Factor</term><term>Receptor, ErbB-2</term></keywords><keywords scheme="MESH" qualifier="chemistry" xml:lang="en"><term>Breast Neoplasms</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Breast Neoplasms</term></keywords><keywords scheme="MESH" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Tumeurs du sein</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Protocoles de polychimiothérapie antinéoplasique</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Disease-Free Survival</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Middle Aged</term><term>Survival Rate</term><term>Tissue Array Analysis</term><term>Trastuzumab</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Analyse sur puce à tissus</term><term>Femelle</term><term>Humains</term><term>Immunofluorescence</term><term>Récepteur facteur croissance épiderme</term><term>Association</term><term>Cancer du sein</term><term>Survie sans rechute</term><term>Taux de survie</term><term>Trastuzumab</term><term>Essai clinique</term><term>Récepteur facteur croissance</term><term>Marqueur biologique</term><term>Dosage</term><term>Cancérologie</term><term>Anticancéreux</term><term>Immunomodulateur</term><term>Tumeurs du sein</term><term>Études de suivi</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Association</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Background: Epidermal growth factor receptor (EGFR) has been hypothesised to modulate the effectiveness of anti-HER2 therapy. We used a standardised, quantitative immunofluorescence assay and a novel EGFR antibody to evaluate the correlation between EGFR expression and clinical outcome in the North Central Cancer Treatment Group (NCCTG) N9831 trial. Methods: Tissue microarrays were constructed that allowed analysis of 1365 patients randomly assigned to receive chemotherapy alone (Arm A), sequential trastuzumab after chemotherapy (Arm B) and chemotherapy with concurrent trastuzumab (Arm C). Measurement of EGFR was performed using the EGFR antibody, D38B1, on the fluorescence-based AQUA platform. The result was validated using an independent retrospective metastatic breast cancer cohort (n=130). Results: Epidermal growth factor receptor assessed as a continuous (logarithmic transformed) variable shows an association with disease-free survival in Arm C (P= 0.009) but not in Arm A or B. High EGFR expression was associated with worse outcome (Hazard ratio (HR) = 2.15; 95% CI 1.28-3.60, P= 0.004). Validation in a Greek metastatic breast cancer cohort showed an HR associated with high EGFR expression of 1.92 (P=0.0073). Conclusions: High expression of EGFR appears to be associated with decreased benefit from adjuvant concurrent trastuzumab. Since other treatment options exist for HER2-driven tumours, further validation of these data may select patients for alternative or additive therapy.</div></front></TEI><affiliations><list><country><li>France</li><li>Grèce</li><li>États-Unis</li></country><region><li>Attique (région)</li><li>Île-de-France</li></region><settlement><li>Athènes</li><li>Paris</li></settlement></list><tree><country name="États-Unis"><noRegion><name sortKey="Cheng, H" sort="Cheng, H" uniqKey="Cheng H" first="H." last="Cheng">H. Cheng</name></noRegion><name sortKey="Ballman, K" sort="Ballman, K" uniqKey="Ballman K" first="K." last="Ballman">K. Ballman</name><name sortKey="Chen, B" sort="Chen, B" uniqKey="Chen B" first="B." last="Chen">B. Chen</name><name sortKey="Davidson, N E" sort="Davidson, N E" uniqKey="Davidson N" first="N. E." last="Davidson">N. E. Davidson</name><name sortKey="Dueck, A C" sort="Dueck, A C" uniqKey="Dueck A" first="A. C." last="Dueck">A. C. Dueck</name><name sortKey="Gralow, J" sort="Gralow, J" uniqKey="Gralow J" first="J." last="Gralow">J. Gralow</name><name sortKey="Hudis, C" sort="Hudis, C" uniqKey="Hudis C" first="C." last="Hudis">C. Hudis</name><name sortKey="Mccullough, A E" sort="Mccullough, A E" uniqKey="Mccullough A" first="A. E." last="Mccullough">A. E. Mccullough</name><name sortKey="Perez, E A" sort="Perez, E A" uniqKey="Perez E" first="E. A." last="Perez">E. A. Perez</name><name sortKey="Reinholz, M M" sort="Reinholz, M M" uniqKey="Reinholz M" first="M. M." last="Reinholz">M. M. Reinholz</name><name sortKey="Rimm, D L" sort="Rimm, D L" uniqKey="Rimm D" first="D. L." last="Rimm">D. L. Rimm</name><name sortKey="Tenner, K" sort="Tenner, K" uniqKey="Tenner K" first="K." last="Tenner">K. Tenner</name></country><country name="France"><region name="Île-de-France"><name sortKey="Vassilakopoulou, M" sort="Vassilakopoulou, M" uniqKey="Vassilakopoulou M" first="M." last="Vassilakopoulou">M. Vassilakopoulou</name></region></country><country name="Grèce"><noRegion><name sortKey="Fountzilas, G" sort="Fountzilas, G" uniqKey="Fountzilas G" first="G." last="Fountzilas">G. Fountzilas</name></noRegion><name sortKey="Fountzilas, G" sort="Fountzilas, G" uniqKey="Fountzilas G" first="G." last="Fountzilas">G. Fountzilas</name><name sortKey="Psyrri, A" sort="Psyrri, A" uniqKey="Psyrri A" first="A." last="Psyrri">A. Psyrri</name><name sortKey="Psyrri, A" sort="Psyrri, A" uniqKey="Psyrri A" first="A." last="Psyrri">A. Psyrri</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Amérique/explor/PittsburghV1/Data/France/Analysis
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000335 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/France/Analysis/biblio.hfd -nk 000335 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Amérique
|area= PittsburghV1
|flux= France
|étape= Analysis
|type= RBID
|clé= Pascal:14-0250912
|texte= EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial
}}
| This area was generated with Dilib version V0.6.38. |  |